KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other financing activities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 14 years of Other financing activities data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Other financing activities rose 22.22% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $3.7 million, down 40.32%, while the annual FY2025 figure was $3.7 million, 40.32% down from the prior year.
  • Other financing activities reached $1.1 million in Q4 2025 per VRTX's latest filing, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $3.5 million in Q1 2024 and bottomed at -$1.5 million in Q4 2023.
  • Average Other financing activities over 5 years is $1.0 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Other financing activities: surged 1739.08% in 2021, then tumbled 236.36% in 2023.
  • A 5-year view of Other financing activities shows it stood at $1.4 million in 2021, then dropped by 21.43% to $1.1 million in 2022, then crashed by 236.36% to -$1.5 million in 2023, then surged by 160.0% to $900000.0 in 2024, then grew by 22.22% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $700000.0 in Q2 2025.